Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369322 | 0.91 | MKNK1 (0.42) | MKNK1MKNK2CYP17A1ALDH1A1POLB | |
| SCHEMBL1369018 | 0.90 | CYP17A1 (0.46) | MKNK1MKNK2CYP17A1ALDH1A1POLB | |
| SCHEMBL1368624 | 0.86 | CYP17A1 (0.43) | MKNK1MKNK2CYP17A1ALDH1A1POLB | |
| SCHEMBL1369299 | 0.82 | CYP17A1 (0.39) | MKNK1MKNK2CYP17A1ALDH1A1POLB | |
| SCHEMBL2062839 | 0.77 | MKNK1 (0.43) | MKNK1MKNK2CYP17A1ALDH1A1AGER | |
| SCHEMBL1370790 | 0.73 | CYP3A4 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL1367454 | 0.73 | CYP3A4 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL1367453 | 0.73 | CYP3A4 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL886792 | 0.72 | KCNA5 (0.53) | MKNK1MKNK2 | |
| SCHEMBL1369076 | 0.72 | GRM5 (0.36) | ALDH1A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | claimed |
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| EP-1993551-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007089735-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004229-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | MKNK1 428/4885MKNK2 450/4885CYP17A1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.